(For further details, see Arrhythmias → Tachyarrhythmias → Premature Ventricular Contractions)
As previously discussed in the section on arrhythmia classifications, the clinical significance of premature ventricular contractions (PVCs) depends primarily on the presence or absence of underlying structural heart disease.
It is worth noting that, in clinical practice, the boundary between the presence and absence of structural heart disease is not always clear-cut. Patients may present with minimal, early-stage, or highly localized histological myocardial alterations that are not immediately visible on conventional imaging modalities. This fine line necessitates a meticulous diagnostic approach, as even a minor underlying disease process can impact the patient’s long-term follow-up and overall management.
Catheter Ablation of PVCs in Patients Without Structural Heart Disease
Frequent premature ventricular contractions in patients without structural heart disease share common characteristics with idiopathic ventricular tachycardias. While the clinical manifestation of the arrhythmic phenomenon obviously differs, both conditions undergo the same diagnostic workup and follow similar therapeutic strategies. Treatment is indicated when symptoms are present or when the arrhythmic burden is high enough to induce manifestations of cardiac dysfunction. Pharmacotherapy and catheter ablation constitute the two primary therapeutic modalities. Catheter ablation can provide a definitive cure and is therefore preferred in highly symptomatic patients.
Indications for Catheter Ablation
Catheter ablation is indicated for the following patient categories:
- Patients with symptomatic, frequent premature ventricular contractions despite optimal medical therapy.
- Symptomatic patients with a high PVC burden who prefer not to receive long-term pharmacotherapy.
- Patients who experience adverse effects from medical therapy.
- The administration of antiarrhythmic medications (e.g., beta-blockers) can cause side effects—such as significant bradycardia—potentially exacerbating the patient’s symptoms. Although amiodarone is perhaps the most potent drug for suppressing ventricular ectopy, it should be avoided due to its severe side-effect profile, at least as a first-line treatment.
- Asymptomatic patients with a high arrhythmic burden (>10,000 premature ventricular contractions per 24 hours) who exhibit evidence of deteriorating cardiac function secondary to the arrhythmia (tachycardia-induced cardiomyopathy).
Procedural Objectives
The objective of the procedure is the focal ablation ("cauterization") of the arrhythmogenic substrate generating the ventricular ectopy. A standard 12-lead electrocardiogram (ECG) can already indicate the site of origin of the premature ventricular contractions. Thus, the target site for successful ablation can be predicted prior to the procedure. However, precise localization is achieved via detailed electroanatomical mapping during the procedure, where energy is directly delivered to the source. A successful outcome entails the complete elimination of any arrhythmia originating from that specific focus.
Occasionally, during mapping in patients with ventricular tachycardia previously classified as idiopathic, areas of low electrical voltage are identified, which may be associated with the etiology of the tachycardia. Advanced, highly sensitive mapping techniques used during electrophysiological studies (EPS) can reveal small-scale pathological myocardial regions. These areas may remain undetected pre-procedurally, even with highly sensitive imaging modalities such as cardiac magnetic resonance imaging (CMR). These findings underscore the need for closer follow-up and potentially a more extensive risk stratification for arrhythmic events.
Pre-procedural Patient Preparation
The ablation procedure does not require extensive preparation by the patient. General guidelines include:
- Discontinuation of all antiarrhythmic medications for at least 5 days prior to the procedure.
- If the patient is on amiodarone, a significantly longer washout period is required (>20 days).
- If the patient takes anticoagulants or other antithrombotic medications, prior consultation with their physician is required to receive instructions regarding peri-procedural medication management.
- All other chronic medications may be continued normally, including on the day of the procedure.
- The patient must remain nil per os (NPO) on the morning of the procedure (a standard dinner the previous evening is permitted). If the procedure is scheduled for the afternoon, a light breakfast may be consumed.
- Upon hospital admission, the patient must bring all prior diagnostic workups, particularly previous electrocardiograms.
The Ablation Procedure
Most commonly, the procedure is performed under local anesthesia at the puncture sites without general anesthesia. However, if the procedure is not well tolerated, deep sedation is utilized.
In the electrophysiology (EP) laboratory, the patient is placed under continuous electrocardiographic monitoring. Following the administration of local anesthesia, femoral venous access is obtained via percutaneous punctures to introduce specialized vascular sheaths. Through these sheaths, electrophysiology catheters (small electrodes) are advanced and positioned at specific sites within the cardiac chambers. Concurrently, a steerable ablation catheter is introduced, capable of performing both mapping and energy delivery.
If the PVC focus originates from the right ventricle, the catheter is introduced via the femoral vein, advanced through the inferior vena cava into the right atrium, and passed across the tricuspid valve into the right ventricle. If the focus is located in the left ventricle or the aortic root, the catheter is inserted via the femoral artery and retrogradely guided through the aorta into the left ventricular cavity. A secondary approach to the left ventricle involves transseptal puncture (accessing the left atrium through the interatrial septum that separates the right and left atria). In rare cases, access via the coronary sinus and cardiac veins or an epicardial approach may be required.
The catheters record electrical signals directly from the endocardium, which are projected onto the laboratory’s mapping systems. For the ablation of ventricular ectopy or ventricular tachycardia, a three-dimensional (3D) electroanatomical mapping system is utilized. This allows real-time visualization and navigation of the catheters without the need for fluoroscopy. The 3D system further aids in constructing a detailed anatomical shell of the heart that depicts the electrical activation sequence. This data allows the precise localization of the PVC or ventricular tachycardia focus for targeted energy delivery.
The introduction of Pulsed Field Ablation (PFA) in recent years, which is now also applied to ventricular ectopy ablation, has significantly contributed to achieving superior therapeutic outcomes.
One potential challenge encountered during these procedures is the intraoperative suppression of the arrhythmia, which impedes detailed activation mapping. This issue is mitigated by careful patient selection (targeting those with a high arrhythmic burden) and intraoperative maneuvers, such as the intravenous infusion of isoproterenol to induce the arrhythmia, or the utilization of pace-mapping techniques.
The procedural endpoint is the complete elimination of any arrhythmia arising from the targeted focus. If this result remains stable for approximately 30 minutes following the final energy application, the procedure is concluded. Hemostasis is achieved at the puncture sites, and the patient is transferred to the ward, potentially after a brief stay in the recovery area.
Post-procedural Care
Immediately after the procedure, the patient returns to the ward, where they remain on strict bed rest. For the first few hours, the patient must avoid vigorous movement of the lower extremities. Mobilization can take place later the same day or the following morning. The next morning, a standard 12-lead ECG is performed, and the patient is discharged with specific post-operative instructions. Routine physical activities can be resumed normally two days after the procedure.
Periodic follow-up assessments must be scheduled according to the physician’s instructions to monitor for arrhythmia recurrence. Furthermore, the patient must undergo evaluation if symptoms reoccur.
Expected Outcomes
The expected success rate of the procedure, achieved in over 85% of cases, is the complete elimination of the premature ventricular contractions originating from the ablated focus. Despite an acutely successful intraoperative result, there is a 10–20% recurrence rate of PVCs. Recurrence typically occurs because the minor tissue lesions caused by the therapeutic ablation heal, allowing the arrhythmogenic focus to recover. If recurrence occurs, the ablation procedure can be repeated.
Procedural Risks and Complications
Catheter ablation for premature ventricular contractions is a highly safe procedure, with an overall complication rate ranging from 0% to 3%.
Potential adverse events include:
- Access Site Hematoma: Located at the percutaneous puncture sites.
- Cardiac Tamponade: This involves the extravasation of blood from the heart into the pericardial sac (the protective membrane surrounding the heart). Cardiac tamponade is a rare complication in this specific procedure. It is a medical emergency requiring immediate pericardiocentesis to aspirate the accumulated blood. This intervention is typically definitive. A small indwelling drainage catheter remains in the pericardial space for approximately 24 hours before removal, during which time the patient is closely monitored. This complication typically extends the hospital stay by 2 to 4 days.
- Atrioventricular (AV) Block: This is a rarely reported complication. It typically results from the inadvertent delivery of energy damaging the His bundle when the arrhythmogenic focus is located in close proximity to the native conduction system.
- Coronary Artery Injury: Secondary to catheter manipulation (isolated case reports).
Catheter Ablation of PVCs in Patients with Structural Heart Disease
In contrast to patients with a structurally normal heart, the presence of underlying cardiac pathology (such as a prior myocardial infarction, ischemic cardiomyopathy, or dilated cardiomyopathy) significantly alters the procedural landscape. In this cohort, premature ventricular contractions are frequently not merely an isolated, symptomatic nuisance; they can serve as the primary trigger for life-threatening ventricular tachycardias.
The objective of ablation in this setting is twofold: to improve global ventricular function by reducing the total arrhythmic burden, and to protect the patient against severe, life-threatening arrhythmic events. Substrate mapping in these patients is highly complex, as the arrhythmogenic foci are typically located within or around areas of myocardial scar tissue. Although the procedure requires a highly specialized approach and the risk of recurrence may be slightly higher, catheter ablation provides substantial clinical benefit and reduces the requirement for high-dose antiarrhythmic pharmacological therapy.